Skip to main content Back to Top
Advertisement

5/19/2022

Tocilizumab Injection

Products Affected - Description

    • Actemra subcutaneous solution for injection, Genentech, 162 mg/0.9 mL, prefilled syringe, NDC 50242-0138-01
    • Actemra ACTPen subcutaneous solution for injection, Genentech, 162 mg/0.9 mL, prefilled syringe, NDC 50242-0143-01

Reason for the Shortage

    • Genentech has Actemra IV on shortage due to unexpected increased demand. Status updates can be found at: https://www.gene.com/contact-us/customer-service/product-distribution/purchasing-actemra

Available Products

    • Actemra intravenous solution for injection, Genentech, 20 mg/mL, 10 mL vial, NDC 50242-0136-01
    • Actemra intravenous solution for injection, Genentech, 20 mg/mL, 20 mL vial, NDC 50242-0137-01
    • Actemra intravenous solution for injection, Genentech, 20 mg/mL, 4 mL vial, NDC 50242-0135-01

Estimated Resupply Dates

    • Genentech also has Actemra 162 mg prefilled syringes and Actemra ACTPen on allocation.

Alternative Agents & Management

    • NIH has provided treatment options for hospitalized patients with Covid-19. These can be found at: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/

Updated

Updated May 19, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 3, 2021 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.